Drug intelligence / Profile preview

Alterome Therapeutics undisclosed KRAKEN-guided program

Development stage: Preclinical
Lead developer: Alterome Therapeutics
Modality: Small Molecules

Overview

Alterome Therapeutics is developing an undisclosed small molecule program for the treatment of solid tumors. This program is part of the company's precision oncology pipeline and utilizes their proprietary KRAKEN (Kinetic Reservoir of Alteration-specific Knowledge and ENgineering) platform. The KRAKEN platform integrates structural biology, machine learning, and chemistry to identify and target specific oncogenic alterations that are difficult to drug. As of early 2024, the specific biological target and active ingredient remain undisclosed, and the program is in the discovery stage of development.

Other names: Undisclosed KRAKEN-Guided program

Beyond the preview

Go deeper on Alterome Therapeutics undisclosed KRAKEN-guided program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alterome Therapeutics undisclosed KRAKEN-guided program.

Explore the full profile